Once-Weekly Exenatide Flops Against Liraglutide

EASD 2011 — LISBON — A trial failed to prove that once-weekly injections of exenatide (Bydureon) were equal to daily injections of liraglutide (Victoza) in reducing glycosylated hemoglobin A1c in type 2 diabetes patients, researchers reported here.


< Back to Listings